aripiprazole

(redirected from Abilify Maintena)
Also found in: Medical.
Related to Abilify Maintena: aripiprazole, Invega Sustenna

a·ri·pip·ra·zole

 (ā′rə-pĭp′rə-zōl′)
n.
An antipsychotic drug, C23H27Cl2N3O2, that functions as a partial dopamine receptor agonist and is used to treat schizophrenia, bipolar disorder, and, in combination with other drugs, depression.

[Perhaps from shortening and alteration of the name of Arvid Carlsson (born 1923), Swedish pharmacologist and Nobel laureate who identified the role of dopamine as a neurotransmitter in the brain and suggested the possibility of developing partial dopamine receptor agonists as treatments for psychosis + pip(e)raz(ine) + -ole.]
Translations

aripiprazole

n aripiprazol m
Mentioned in ?
References in periodicals archive ?
Revenue of Abilify Maintena increased 23% to DKK 951 million (20% in local currencies)
Aripiprazole intramuscular depot formulation Abilify Maintena (once-monthly injection), one of the drugs launched under the global alliance with H.
During the year, revenues of Abilify Maintena increased by 20% to DKK 1,595m, or 23% in local currencies; revenues of Brintellix/Trintellix increased by 31% to DKK2,182m, or 37% in local currencies; revenues of Northera increased by 10% to DKK1,806m, or 15% in local currency; revenues of Onfi increased by 5% to DKK3,165m, or 12% in local currency; revenues of Rexulti increased by 38% to DKK1,723m, or 44% in local currencies; revenues in North America increased by 1% to DKK10,743m, or 6% in local currencies; revenues in International Markets increased by 3% to DKK3,500m, or 10% in local currencies and revenues in Europe increased by 6% to DKK2,970m, or 6% in local currencies.
Lundbeck reports approval by US FDA of Abilify Maintena for extended-release injectable suspension for maintenance monotherapy treatment of bipolar I disorder (BP I) in adults
A The mental health drug aripiprazole (available under the brand names Abilify, Abilify Maintena, Aristada, and also sold as a generic drug) is used to treat major depressive disorder, schizophrenia, bipolar disorder, Tourette syndrome, and irritability linked to autistic disorder.
In January 2016, we initiated the treatment with Abilify Maintena, 1 ml i.m., in conjunction with Abilify, 10 mg/day p.o., Romparkine, 2 mg x 1 + 1/2/day, Seroquel XR, 200 mg x 1/2/day and Gerodorm, 40 mg x 1/day.
* The main driver of growth in the bipolar disorder market will be the uptake of novel atypical antipsychotic products, such as Otsuka/Lundbeck's Abilify Maintena and Allergan/Gedeon Richter/Mitsubishi Tanabe's Vraylar.
Food and Drug Administration (FDA) approved the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension.
(Otsuka) today announced marketing authorisation approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.
Consolidated business profit, operating profit, profit before taxes, profit and profit attributable to owners of the company are projected to exceed the previous forecast because sales of four global products (Abilify Maintena, Rexulti, Samsca/JINARC/JYNARQUE and Lonsurf) in particularsales ofJYNARQUE in U.S.
FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada).
M2 PHARMA-February 17, 2014-Otsuka and Lundbeck receive approval for 'Abilify Maintena' from Health Canada